AbCellera Biologics Inc. discovers and develops antibody-based medicines for unmet medical needs in the United States. Its lead product candidates include ABCL635, a non-hormonal medicine in Phase 2 trials for moderate-to-severe vasomotor symptoms, and ABCL575, a fully human, half-life extended monoclonal antibody in Phase 1 trials for T-cell-mediated autoimmune conditions such as atopic dermatitis. The company has research collaborations and license agreements with Eli Lilly, AbbVie, and Jazz Pharmaceuticals for T-cell engaging multispecific antibodies, as well as partnerships with Viking Global Investors, ArrowMark Partners, Biogen, and Vertex Pharmaceuticals for multispecific T-cell engagers for autoimmune diseases. Incorporated in 2012, AbCellera is headquartered in Vancouver, Canada.
AbCellera's hot-flash drug success and Jazz deal offset weak Q2
▲
Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
▼
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
▲
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.
Q3 2026
▲2▼1
AbCellera's hot-flash drug success and Jazz deal offset weak Q2
▲
Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.
This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.
▼
Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.
This is a new financial report showing deteriorating results, which weighs on the stock price.
▲
ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.
This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.
News & notes movingABCL
Canada
ABCL▼
AbCellera Biologics prices oversubscribed $200M offering at $9.75 per share
AbCellera Biologics has priced its oversubscribed underwritten public offering of 17.44 million common shares at $9.75 per share. The company is also offering pre-funded warrants to purchase up to 3.08 million common shares at $9.74999 per warrant, representing the public offering price minus a $0.00001 exercise price. Gross proceeds from the offering are expected to be approximately $200.0 million, with all securities sold directly by AbCellera and closing expected on August 14, 2026. The company plans to use the net proceeds to fund research, development, and clinical advancement of its internal pipeline, including its lead clinical program ABCL635, as well as for working capital and general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are acting as joint book-running managers for the transaction.
Silence Therapeutics and AbCellera Biologics Surge on Positive Trial Data
Silence Therapeutics and AbCellera Biologics reached 52-week highs on Monday after releasing positive clinical trial results. Silence Therapeutics shares jumped over 29% to $17.58 after reporting that its siRNA candidate Divesiran met the primary endpoint in a Phase 2 trial for Polycythemia vera, with response rates of 93% and 81% in two dosing groups. AbCellera Biologics stock climbed more than 34% to $10.01 after its drug ABCL635 met the primary endpoint in a Phase 2 trial for vasomotor symptoms associated with menopause, reducing moderate-to-severe symptoms in about 83% of patients after a single dose. Other biotech stocks hitting 52-week highs included Cumberland Pharmaceuticals, Celldex Therapeutics, and Biodesix, driven by quarterly results and pipeline updates.
AbCellera Surges 41% After Hot-Flash Drug Shows Strong Mid-Stage Trial Results
AbCellera Biologics Inc. jumped as much as 41%, giving it a market value of almost $3 billion, after the company announced that its potential remedy for hot flashes was effective in a mid-stage trial. The clinical trial evaluated the treatment in 92 postmenopausal women who were given either the drug or a placebo, and the experimental shot reduced the frequency and severity of hot flashes over a four-week study period compared with a placebo, with no serious side effects. Chief Executive Officer Carl Hansen said the efficacy data exceeded even the most aggressive upside scenario the company had considered, and he believes the product has blockbuster potential. The drug aims to block a biological signal associated with hot flashes and would be a non-hormonal treatment, which Hansen noted has significant market potential because hormone therapies currently available are unsuitable for 20% of women. Shares of the Vancouver-based company were up 32% to $9.17 in US trading shortly before 12 p.m. Monday, though the drug still faces further clinical trials.
AbCellera Biologics announced positive top-line results from the Phase 2 portion of its Phase 1/2 trial of ABCL635, an investigational antibody for moderate-to-severe vasomotor symptoms due to menopause. The study met its primary efficacy endpoints, achieving statistically significant reductions in both frequency and severity of hot flashes at week 4 compared to placebo after a single subcutaneous 600 mg dose. Patients receiving ABCL635 experienced an average reduction of 8.8 moderate-to-severe events per day versus 3.5 for placebo, a placebo-adjusted difference of 5.3, translating to an 83% reduction in frequency compared to 33% for placebo. Severity scores improved with a mean reduction of 1.4 points versus 0.3 for placebo, a placebo-adjusted difference of 1.1, and a mean percent reduction in severity of 58% for ABCL635 compared to 12% for placebo. The treatment was well tolerated with no serious adverse events or discontinuations, and the stock surged 33% in pre-market trading.
AbCellera Reports Q2 2026 Net Loss Widens to $55 Million as Revenue Falls to $4 Million
AbCellera Biologics reported a net loss of roughly $55 million for the second quarter of 2026, up from a $35 million loss a year earlier, while total revenue dropped to approximately $4 million from $17 million. The company completed enrollment for the phase 2 study of ABCL-635 in treating hot flashes ahead of schedule, with top-line data expected soon, and secured new T-cell engager collaborations with Vertex and Jazz Pharmaceuticals that added over $110 million in upfront cash. AbCellera maintains a strong liquidity position with over $565 million in cash and equivalents plus roughly $110 million in committed government funding, providing a runway of at least three years. Research and development expenses increased by about $7 million year-over-year, and the company missed its internal goal of moving another program into IND-enabling activities in the first half of 2026. The upcoming phase 2 data for ABCL-635 carries scientific risks, including the unresolved question of whether blocking NK3R in the pre-optic nucleus is necessary for efficacy, and the company acknowledged a pronounced placebo response in similar trials.
Vertex Pharmaceuticals to acquire Crinetics Pharmaceuticals in third quarter of 2026
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026, aiming to broaden its pipeline beyond cystic fibrosis into endocrine and rare diseases. Vertex reported second-quarter 2026 revenue of US$3,333.9 million and net income of US$1,099.8 million, and raised its full-year 2026 revenue guidance to a range of US$13.1 billion to US$13.2 billion. The acquisition comes alongside a recent collaboration with AbCellera on T cell engagers for autoimmune diseases, positioning Vertex against large biotech peers such as Regeneron and Amgen. Investors will watch for integration plans, R&D spending, and clinical progress as the deal approaches closing.
AbCellera Biologics appoints Dr. Victor Sandor to board, Truist raises price target to $12
AbCellera Biologics appointed Dr. Victor Sandor to its Board of Directors as an independent director on June 5. Dr. Sandor is a medical oncologist who previously served as Chief Medical Officer at Array BioPharma, where he helped secure approval for Braftovi and Mektovi. Earlier, on May 21, Truist Securities raised its price target on AbCellera Biologics from $10 to $12 while maintaining a Buy rating, citing positive Phase 1 results for ABCL-635 that showed target engagement and a clean safety profile. Truist expects Phase 2 data in the third quarter of 2026 to match or exceed the effectiveness of Veozah and Lynkuet, and views the stock as offering an attractive risk-reward opportunity ahead of those results.
VERAXA Biotech shareholders urged to watch antibody therapeutics sector deals
Strategic licensing agreements and acquisitions in antibody-drug conjugates and T-cell engager therapeutics continue to create significant value for platform companies well before pivotal clinical trials. The Jazz Pharmaceuticals–AbCellera collaboration exemplifies how differentiated antibody technologies can command substantial financial commitments prior to clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two modalities that continue to attract strategic partnerships. Recent transactions demonstrate that pharmaceutical companies are actively seeking access to differentiated antibody engineering capabilities rather than waiting for late-stage clinical assets.
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Competition
Biotech & Genomic Medicine › AI Drug Discovery Technology
VACH · Demand · Positive VERAXA Biotech is positioned as having a platform across ADCs and T-cell engagers, which are attracting strategic partnerships, implying potential demand.
ABCL · Demand · Positive AbCellera's collaboration with Jazz Pharmaceuticals is cited as an example of a strategic licensing deal, indicating demand for its antibody platform.
JAZZ · Demand · Positive Jazz Pharmaceuticals' collaboration with AbCellera is highlighted as a significant strategic partnership, showing demand for differentiated antibody technologies.
Jazz Pharmaceuticals expands AbCellera tie-up as Zepzelca trial misses goal
Jazz Pharmaceuticals expanded its collaboration with AbCellera Biologics to develop next-generation T-cell multispecific antibodies for gastrointestinal and other solid tumors. The company also reported that the Phase 3 LAGOON trial of Zepzelca in second-line small cell lung cancer did not meet its primary endpoint. Zepzelca retains its first-line approval based on prior studies, and Jazz is in discussions with the FDA about future steps. Management indicated that current financial guidance is unchanged.
Jazz Pharmaceuticals and AbCellera Partner on Next-Generation Solid Tumor Therapies
Jazz Pharmaceuticals and AbCellera Biologics have entered a preclinical research collaboration to discover and develop next-generation T-cell-engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. Under the deal, Jazz will make upfront payments totaling $56 million for the first two discovery programs, with an additional $28 million due upon initiation of a third program within 12 months. For each program Jazz advances, AbCellera is eligible to receive up to $792 million in option fees and milestone payments, plus tiered royalties on future net sales ranging from the mid-single digits to the low double digits. Jazz gains access to AbCellera's antibody discovery platform and T-cell engager technology, while retaining exclusive options to develop and commercialize resulting therapeutic antibodies. The collaboration may expand by up to two additional programs by mutual agreement.
Biotech & Genomic Medicine › AI Drug Discovery ▲Technology
Biotech & Genomic Medicine › Oncology Therapeutics Competition
ABCL · Technology · Positive AbCellera's antibody discovery platform and T-cell engager technology are central to the collaboration, with upfront payments and potential milestones up to $792M per program.
JAZZ · Technology · Positive Jazz gains access to AbCellera's platform to develop next-generation T-cell-engaging multispecific antibodies for solid tumors, with exclusive options to commercialize.
USA